{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-22-000003","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2022-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.114176+00:00","generated_at":"2026-06-27T15:41:40.283538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vertex reports Q4 2021 product revenue $2.07B (+27% YoY); guides 2022 revenue $8.4-$8.6B","bullets":["Full-year 2021 product revenue $7.57B (+22% YoY); GAAP diluted EPS $9.01, Non-GAAP $13.02.","Q4 2021 GAAP net income $770M ($3.00 diluted EPS); Non-GAAP $866M ($3.37).","FY 2022 product revenue guidance $8.4-$8.6B; combined Non-GAAP R&D+SG&A $2.70-$2.75B.","KAFTRIO approved in EU/UK for CF children 6-11; new reimbursement agreements in Spain and Netherlands.","Pipeline: VX-147 AMKD Phase 2 POC met; VX-880 T1D Day 150 data shows insulin reduction; CTX001 enrollment complete."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-22-000003","json":"https://secwatch.observer/filing/0000875320-22-000003.json","markdown":"https://secwatch.observer/filing/0000875320-22-000003.md","text":"https://secwatch.observer/filing/0000875320-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000003/0000875320-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000003/vrtx-20220126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:41:40.283538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}